Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

6.60USD
16 Feb 2018
Change (% chg)

$-0.02 (-0.30%)
Prev Close
$6.62
Open
$6.64
Day's High
$6.72
Day's Low
$6.42
Volume
22,674
Avg. Vol
21,867
52-wk High
$21.59
52-wk Low
$6.10

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $70.18
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage:

Nov 13 2017

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

Sep 19 2017

BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​

* Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​ Source text: (http://bit.ly/2vRDX2x) Further company coverage:

Sep 01 2017

Earnings vs. Estimates